Form 8-K - Current report:
SEC Accession No. 0001437749-22-019919
Filing Date
2022-08-11
Accepted
2022-08-11 07:05:47
Documents
13
Period of Report
2022-08-09
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K arav20220810_8k.htm   iXBRL 8-K 27582
  Complete submission text file 0001437749-22-019919.txt   163529

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA arav-20220809.xsd EX-101.SCH 3601
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE arav-20220809_def.xml EX-101.DEF 11919
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE arav-20220809_lab.xml EX-101.LAB 15966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arav-20220809_pre.xml EX-101.PRE 12130
7 EXTRACTED XBRL INSTANCE DOCUMENT arav20220810_8k_htm.xml XML 2655
Mailing Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098
Business Address RIVER OAKS TOWER 3730 KIRBY DRIVE, SUITE 1200 HOUSTON TX 77098 936-355-1910
Aravive, Inc. (Filer) CIK: 0001513818 (see all company filings)

EIN.: 264106690 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36361 | Film No.: 221153634
SIC: 2834 Pharmaceutical Preparations